Special Issue "Drug Development and Treatment for Neurological Disease"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 31 July 2023 | Viewed by 133

Special Issue Editors

College of Medicine and Health Sciences United Arab Emirates University, Al-Ain, United Arab Emirates
Interests: drug development; behavioral neuropharmacology; neuroscience; drug targeting
Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates
Interests: pharmacotherapy; clinical science, biomarkers; aging; drug repurposing

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue of Pharmaceutics (2021 impact factor: 6.525) entitled “Drug Development and Treatment for Neurological Disease”

Neurological disorders and their sequelae (direct consequences) affect as many as one billion people worldwide and include Alzheimer’s and Parkinson’s disease, epilepsy, autism spectrum disorder, or Brain damage. Novel therapeutic strategies are required which can either prevent or delay the progression of the disease

This Special Issue aims to highlight the progress and breakthroughs in drug development and treatment for neurological diseases. Research areas may include, but are not limited to, new drug therapeutic targets and biomarkers, new pathological mechanisms, and novel therapeutic agents in order to provide valuable clues for developing new therapeutic strategies for neurological diseases. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Prof. Dr. Bassem Sadek
Dr. Amal Akour
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • brain targeting
  • drug development
  • neurological diseases
  • Alzheimer’s disease
  • Parkinson’s disease
  • drug delivery
  • autism spectrum disorder
  • neurotherapeutics
  • neurological disorders

Published Papers

This special issue is now open for submission.
Back to TopTop